Bicara Therapeutics (BCAX) EBITDA (2023 - 2026)

Bicara Therapeutics has reported EBITDA for 4 years, with the latest figure at -$56.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 53.88% year-over-year to -$56.7 million; the trailing twelve-month figure through Mar 2026 stood at -$162.2 million (down 70.66% YoY), and the FY2025 full-year result was -$137.7 million, down 102.53% from the prior year.
• EBITDA for Q1 2026 stood at -$56.7 million, down from -$37.0 million in the prior quarter.
• The five-year high for EBITDA was -$9.5 million in Q3 2023, with the low at -$56.7 million in Q1 2026.
• Historically, EBITDA has averaged -$26.9 million across 4 years, with a median of -$21.0 million in 2024.
• Annual changes were most pronounced in 2024 — EBITDA tumbled 53.12% — and 2025, when it plunged 139.66%.
• Bicara Therapeutics' EBITDA stood at -$13.7 million in 2023, then tumbled by 53.12% to -$21.0 million in 2024, then sank by 76.59% to -$37.0 million in 2025, then tumbled by 53.21% to -$56.7 million in 2026.
• The last three EBITDA figures came in at -$56.7 million (Q1 2026), -$37.0 million (Q4 2025), and -$36.5 million (Q3 2025), per Business Quant data.